Abstract
THERE is evidence for the existence of multiple forms of dopamine (DA) receptors1–3. In particular, some of these receptors are coupled to adenylate cyclase (DA-stimulating enzyme activity), whereas others seem to be independent3–5. These two classes of receptors, which have been designated D-1 and D-2, respectively, would also have different pharmacological properties3. Pituitary mammotroph DA receptors regulating prolactin (PRL) secretion are considered to be typical D-2 receptors. A DA-stimulated adenylate cyclase has not been detected in normal anterior pituitaries3,5,6; furthermore, several studies indicate that cyclic AMP is stimulatory and not inhibitory to PRL secretion7,8. We report here that in homogenates of human PRL adenomas, in which dopaminergic agonists act as inhibitors of PRL secretion, basal adenylate cyclase is inhibited by DA. The DA receptors mediating this inhibition have the same pharmacological properties as those regulating PRL secretion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
